CJC-1295

Synthetic growth hormone-releasing hormone analogue; DAC and non-DAC variants are chemically distinct.

29 (peptide chain)Amino acids

~3,647.2Daltons

Varies by formFormula

2000sResearch period

Overview

Choose your reading level:

In plain language

CJC-1295 is a lab-made peptide based on the first 29 amino acids of growth hormone-releasing hormone (GHRH), the brain hormone that tells the pituitary gland to release growth hormone.

It was modified to last much longer in the body. Early human studies showed it raised growth hormone and IGF-1 levels for days after one injection. Its development as a medicine stopped, and it is not FDA-approved. Products sold online are unregulated.

Molecular reference: 29 (peptide chain) amino acids; ~3,647.2 Da. Approximate CJC-1295 with DAC reference; the non-DAC peptide has a different molecular mass. Verify the precise conjugate and salt.

Molecular identity

Amino acids: 29 (peptide chain)
Molecular weight: ~3,647.2 Da
Formula: Form-dependent
Sequence: Modified GHRH(1–29) analogue; variant-specific

Form clarification: Approximate CJC-1295 with DAC reference; the non-DAC peptide has a different molecular mass. Verify the precise conjugate and salt. Molecular weight is a reference value, not a certificate of analysis.

Origin and history

CJC-1295 was created by the Montreal biotech company ConjuChem in the early 2000s. It is a modified version of the first 29 amino acids of growth hormone-releasing hormone (GHRH), with four amino acid swaps for stability and a chemical “Drug Affinity Complex” (DAC) that lets it bond to albumin in the blood, stretching its half-life from minutes to about a week.

A 2006 study in healthy adults showed that one injection raised growth hormone and IGF-1 levels for days. That July, ConjuChem halted a Phase 2 trial in people with HIV-related belly fat after a participant died; the death was not attributed to the drug, but development stalled and it was never approved. The version without DAC, often called “Mod GRF 1-29,” is what many products labeled CJC-1295 actually contain.

Key people

ConjuChemMontreal biotech that developed the DAC technology

Timeline

1982
GHRH is discovered (see Sermorelin)
2005
First animal studies of the albumin-binding GHRH analogue
2006
Human study shows days-long rises in GH and IGF-1
2006
Phase 2 trial halted after a participant’s death
Today
Sold online without approval; not FDA-approved

See every peptide on one history timeline.

Human evidence

PreclinicalEarly humanControlled trialsApproved use

Small human pharmacology studies of CJC-1295 with DAC have been published; clinical benefits and long-term safety are not established.

Trial status, registration and results should be checked directly in clinical registries; enrollment is not proof of benefit.

Do not combine CJC-1295 trial findings with ipamorelin or with a different CJC-1295 variant.

Explore original publications and distinguish preclinical findings from controlled human evidence.

Safety and regulatory status

See every compound on the regulatory tracker.

Not FDA-approved for therapeutic use.

Product identity, purity, sterility, and endotoxin testing address different risks. This profile is educational and does not provide treatment guidance.

Sources

Cite this page

Hernandez Gener, E. (2026, November 7). CJC-1295: molecular data, research history and evidence. VALREXA Biosciences. https://valrexa.com/peptides/cjc-1295.html

APA style · Last reviewed November 7, 2026 · Our editorial standards

Last reviewed November 7, 2026. Trial and regulatory status can change; confirm in the linked registries. This profile is educational and is not medical advice, a treatment recommendation, or dosing or sourcing guidance. Report an error · Corrections policy